Int'l : +1(646) 600-5072 | query@kbvresearch.com
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Global Autoimmune Disease Therapeutics Market, published by KBV research, The Global Autoimmune Disease Therapeutics Market size is expected to reach $149.4 billion by 2025, rising at a market growth of 4.34% CAGR during the forecast period.
The North America market dominated the Global Multiple Sclerosis Market by Region in 2018, growing at a CAGR of 3.9 % during the forecast period. The Europe market is expected to witness a CAGR of 4.1% during (2019-2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 5.9% during (2019-2025).
The Anti-Inflammatory market would dominate the Global Autoimmune Disease Therapeutics Market by Drug Class by 2025growing at a CAGR of 4.5 % during the forecast period. The Anti-Hyperglycemics market is expected to witness a CAGR of 4.7% during (2019-2025).
The Retail Pharmacies and Drug Stores market dominated the Global Autoimmune Disease Therapeutics Market by Distribution Channel in 2018, growing at a CAGR of 4.2 % during the forecast period. The Online market is expected to witness a CAGR of 4.6% during (2019-2025).
Full Report: https://www.kbvresearch.com/autoimmune-disease-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of ABBOTT Laboratories, Bio-Rad Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, AbbVie, Inc., Amgen, Inc. and Novartis AG.
By Indication
By Drug Class
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings from KBV Research